Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

Stock Information for Lyra Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.